CollPlant Biotechnologies Ltd.
As of Oct 22, 2026, CollPlant Biotechnologies is in Stage 1, the basing phase, now in week 5 (since Sep 21, 2026). It closed at $3.62, 84.5% below its 52-week high and below its 200-day average, which is falling.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada,… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CLGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CLGN among Biotechnology492nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …492 | CLGN | Stage 1 · wk 5 | 9 | −10.4% |
CollPlant Biotechnologies: quick answers
What stage is CollPlant Biotechnologies in?
As of Oct 22, 2026, CollPlant Biotechnologies (CLGN) is in Stage 1, the basing phase. It entered Stage 1 on Sep 21, 2026 and is in week 5. What the four stages mean
Is CollPlant Biotechnologies in an uptrend?
Not yet. CollPlant Biotechnologies is in Stage 1, a base that can come before an uptrend. It trades 33.6% below its 200-day average, which is falling.
How far is CollPlant Biotechnologies from its 52-week high?
CollPlant Biotechnologies closed at $3.62 on Oct 22, 2026, 84.5% below its 52-week high of $23.35. Its 52-week low is $2.73.
How has CollPlant Biotechnologies performed over the past year?
As of Oct 22, 2026, CollPlant Biotechnologies is down 84.7% over the past year and down 75.5% so far in 2026.
Which sector and industry is CollPlant Biotechnologies in?
CollPlant Biotechnologies is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.